It has said the move will give equal weight to its UK, Swedish and US listings. The shares gained 2.6% in London, leading the Stoxx 600 Health Care Index. It reflects the growing importance of the US to AstraZeneca’s business and in turn, a relative shift away from its home country as Chief Executive Officer Pascal Soriot looks to the world’s largest pharma market for growth.